How effective is Alecensa for ALK-positive NSCLC?
Alecensa (alectinib) is used to treat anaplastic lymphoma kinase positive non-small cell lung cancer (ALK-positive NSCLC) that has spread to other parts of the body. Alecensa is also used as an adjuvant treatment in adult patients following tumor resection of (ALK)-positive non-small cell lung cancer (NSCLC) when tumors ≥ 4 cm or node positive, as detected by an FDA-approved test.
How effective is Alecensa (alectinib) at treating metastatic ALK+ NSCLC?
The updated results from the ALEX clinical trial (NCT02075840) shows that alectinib (Alecensa) is very effective at treating ALK-positive non-small-cell lung cancer (ALK-positive NSLC cancer), as it significantly prolonged the median progression-free survival to 34.8 months compared to 10.9 months for crizotinib.
For patients with ALK-positive NSLC cancer that has spread to the central nervous system (CNS), alectinib was effective in increasing progression-free survival to 25.4 months compared to 7.4 months for crizotinib .
The recent updated results from the ALEX clinical trial showed a higher 5-year overall survival rate for alectinib of 62.5% compared to 45.5% with crizotinib.
Related questions
- What is the mechanism of action for Alecensa (alectinib)?
- How long do you take Alecensa for?
- How does Alecensa work?
How effective is Alecensa (alectinib) as Adjuvant Treatment of Resected ALK-Positive NSCLC?
Phase III ALINA study showed that Alecensa reduced the risk of disease recurrence or death by 76% compared with platinum-based chemotherapy in people with completely resected IB (tumor ≥ 4 cm) to IIIA ALK-positive NSCLC, in people with ALK-positive early-stage resected non-small cell lung cancer (NSCLC).
Bottom line
ALK-positive metastatic NSCLC
- Alectinib has been shown to increase the median progression-free survival to 34.8 months (compared to 10.9 for crizotinib)
- Alectinib has an increase in the 5-year overall survival rate to 62.5% compared to 45.5% to crizotinib.
Adjuvant Treatment of Resected ALK-Positive NSCLC
- Alecensa reduced the risk of disease recurrence or death by 76% compared with platinum-based chemotherapy.
References
- Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study: https://www.annalsofoncology.org/article/S0923-7534(20)39796-9/fulltext
- Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer: https://www.nejm.org/doi/full/10.1056/nejmoa1704795
- FDA Approves Genentech's Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung Cancer https://www.gene.com/media/press-releases/15023/2024-04-18/fda-approves-genentechs-alecensa-as-firs#:~:text=Genentech%2C%20a%20member%20of%20the,lung%20cancer%20(NSCLC)%20(tumors
Read next
What is the strongest chemotherapy drug for breast cancer?
Doxorubicin is considered one of the strongest chemotherapy drugs for breast cancer ever invented. It can kill cancer cells at every point in their life cycle, and it's used to treat a wide variety of cancers, not just breast cancer. Doxorubicin is also known as “The Red Devil” because it is a clear bright red color. It can cause your urine or other body fluids to turn a reddish color for 1 to 2 days after a dose is given, which is normal and temporary. Continue reading
Is small cell or non-small cell lung cancer worse?
Generally, small cell lung cancer (SCLC) is worse than non-small cell lung cancer (NSCLC). SCLC accounts for about 10-15% of people who have lung cancer and is the most aggressive form of lung cancer. SCLC usually starts in the breathing tubes (bronchi), and although the cells are small, they grow very quickly and create large tumors. Early on in the course of the disease, there are rarely any symptoms. If caught early (limited-stage disease) 20-25% of people can be potentially cured. Extensive SCLC is more difficult to treat. Continue reading
Is non-small cell lung cancer hereditary?
A hereditary family history of lung cancer is one of the many risk factors for developing non-small cell lung cancer. About 8% of lung cancers are thought to be inherited or linked to gene changes, but smoking and air pollution remain the primary causes of lung cancer. Continue reading
Related medical questions
- What is Alecensa used to treat?
- How aggressive is non-small cell lung cancer?
- Does smoking cause non-small cell lung cancer?
- What type of prostate cancer is Erleada used to treat?
- What type of lung cancer is Vizimpro used to treat?
- What type of cancer is Tecentriq used to treat?
- What type of cancer is Daurismo (glasdegib) used to treat?
- Oxycodone vs Hydrocodone - How do they compare?
- Does omeprazole cause cancer?
- Why is Xanax so addictive?
- How do you increase platelet count during chemotherapy?
- Does Ozempic cause cancer?
- Vicodin vs Percocet: What's the difference?
- What are monoclonal antibodies?
- How do I know if immunotherapy is working?
- Why give Taxol (Paxel) before carboplatin?
- What is Quercetin and what are its health benefits?
- What are anti-VEGF drugs (VEGF inhibitors)?
- My stool has changed color. What does it mean?
- Opdivo vs Opdivo Qvantig: What is the Difference?
- How do I know if Aldara is working for skin cancer?
- How does Ibrance kill cancer?
- Does Xolair cause cancer?
- Does Skyrizi cause cancer?
- Is food coloring bad for you?
- What is a chemotherapy regimen?
- Can Tymlos cause bone cancer?
- How do Herceptin (trastuzumab) and Perjeta (pertuzumab) work together?
Drug information
- Alecensa Information for Consumers
- Alecensa prescribing info & package insert (for Health Professionals)
- Side Effects of Alecensa (detailed)
- Alecensa user reviews (2)
Related support groups
- Alecensa (5 questions, 4 members)
- Cancer (180 questions, 643 members)
- Non-Small Cell Lung Cancer (53 questions, 70 members)